Sign in to view content

The 12-Month Safety Results of the PRIMAvera Clinical Trial

Lisa C. Olmos de Koo, MD, MBA

Video
Published 2025

Related

Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Comparison of Visual Evoked Potentials Between Retina Prosthetic Vision, Simulated Low Visual Acuity and Normal Vision
Sandra R Montezuma, MD
On Demand Cases, Courses, and Papers
2020
Quantitative Contrast Sensitivity Longitudinal Changes Correlate Better Than Visual Acuity With Geographic Atrophy Progression
John B. Miller, MD
Annual Meeting Talks
2024

Category: AMD-Non-Neovascular

See more